Study guide

4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms

Key Takeaways Explain This Topic AI

B-ALL is the most prevalent pediatric malignancy (peak incidence 2–5 years), presenting with bone marrow failure, bone pain, hepatosplenomegaly, and sanctuary involvement in the CNS and testes.

Lymphoblasts display high N:C ratios, condensed/fine chromatin, inconspicuous nucleoli, scant agranular cytoplasm, and strict absence of Auer rods, contrasting with larger myeloblasts.

Precursor lymphoid immunophenotyping utilizes TdT and CD34 alongside lineage-defining markers: CD19, CD22, CD79a, and CD10 (CALLA) in B-ALL; cytoplasmic CD3 (cyCD3), CD7, CD2, and CD5 in T-ALL.

T-ALL classically presents in adolescent males as an anterior mediastinal mass with high leukocyte counts, marked by cytoplasmic CD3 positivity and focal polar acid phosphatase staining.

Cytogenetic risk stratification identifies hyperdiploidy (>50 chromosomes) and ETV6::RUNX1 [t(12;21)] as highly favorable, whereas BCR::ABL1 [t(9;22) p190] and KMT2A [t(4;11)] confer poor prognosis.

Last updated: August 2026

Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms

Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma (ALL/LBL) is a heterogeneous group of aggressive hematologic malignancies characterized by the clonal proliferation, arrest of differentiation, and accumulation of immature lymphoid progenitor cells (lymphoblasts) of either B-cell or T-cell lineage in the bone marrow, peripheral blood, and extramedullary sanctuary sites. ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • B-CELL PRECURSOR ALL (B-ALL) T-CELL PRECURSOR ALL (T-ALL)
  • 80–85% of cases; peak age 2–5 yrs • 15–20% of cases; adolescent males
  • Immunophenotype: CD19+, CD22+, CD79a+, • Immunophenotype: cyCD3+ (lineage),
  • Pax-5+, TdT+, CD34+, CD10 (CALLA)+ CD7+ (early), CD2+, CD5+, CD1a+, TdT+
  • Genetics: • Clinical: Anterior mediastinal mass,
  • Favorable: Hyperdiploidy, ETV6::RUNX1 high WBC count (>100 x 10^9/L), rapid
  • Unfavorable: BCR::ABL1 (p190), KMT2A • Cytochemistry: Focal polar Acid Phosphatase
  • 1. Epidemiology & Clinical Manifestations
  • Epidemiological Patterns

B-Lymphoblastic Leukemia (B-ALL): Represents approximately 80 to 85 % 80\text{ to }85\% 80 to 85% of childhood ALL cases. It is the single most common childhood malignancy, exhibiting a sharp peak in incidence between 2 and 5 years of age . A second, smaller incidence rise occurs in adults over 50 years of age.

T-Lymphoblastic Leukemia (T-ALL): Accounts for 15 to 20 % 15\text{ to }20\% 15 to 20% of ALL cases. It demonstrates a distinct demographic predilection for adolescent and young adult males ( M : F ≈ 3 : 1 M:F \approx 3:1 M : F ≈ 3 : 1 ).

Clinical Presentation & Sanctuary Sites

Bone Marrow Replacement (Pancytopenia): Rapid expansion of lymphoblasts within medullary spaces suppresses normal hematopoiesis, manifesting as:

Severe Anemia: Pallor, fatigue, lethargy, exertional dyspnea.

Thrombocytopenia: Petechiae, ecchymoses, mucosal epistaxis, gingival hemorrhage.

Neutropenia: Recurrent bacterial and fungal infections, fever of unknown origin.

Musculoskeletal Symptoms: Severe bone pain, arthralgias, refusal to bear weight, and limping in young children, resulting from leukemic expansion stretching the periosteum.

Extramedullary Organ Involvement: Generalized painless lymphadenopathy, marked hepatosplenomegaly, and soft tissue infiltration.

Sanctuary Sites: Anatomical compartments shielded from systemic chemotherapy by physiological barriers:

Central Nervous System (CNS): Manifests as headache, vomiting, papilledema, and cranial nerve palsies (cranial nerves VII and VI). Diagnostic criteria require cytocentrifugation of cerebrospinal fluid (CSF) demonstrating lymphoblasts.

Testes: Painless, firm, unilateral or bilateral testicular enlargement; a classic site of late extramedullary relapse.

T-ALL Mediastinal Syndrome: T-ALL characteristically arises within the thymus, presenting with an anterior mediastinal mass that compresses the trachea and superior vena cava, causing dyspnea, wheezing, orthopnea, and superior vena cava (SVC) syndrome (facial edema, jugular venous distention), accompanied by marked leukocytosis ( > 100 × 10 9 /L >100 \times 10^9\text{/L} > 100 × 1 0 9 /L ).

2. Lymphoblast Cytomorphology vs. Myeloblast Cytomorphology

Distinguishing lymphoblasts from myeloblasts on Wright-Giemsa stained films is the initial critical step in diagnostic triage: BLAST CYTOMORPHOLOGY COMPARISON

  • [ LYMPHOBLAST ] [ MYELOBLAST ]
  • Size: 10–18 µm (Smaller) • Size: 15–20 µm (Larger)
  • N:C Ratio: Very high (>4:1, scant rim) • N:C Ratio: High (Moderate cytoplasm)
  • Chromatin: Dense, condensed, smooth • Chromatin: Delicate, fine, "lacey"
  • Nucleoli: Inconspicuous / Absent (0–2) • Nucleoli: 2 to 5 distinct, prominent
  • Cytoplasm: Scant light blue, agranular • Cytoplasm: Moderate basophilic
  • AUER RODS: STRICTLY ABSENT (0%) • AUER RODS: PRESENT in 30–50%

Morphologic Feature Lymphoblasts (ALL) Myeloblasts (AML)

Cell Size Small to intermediate ( 10 − 18 μ m 10 - 18\,\mu\text{m} 10 − 18 μ m ) Intermediate to large ( 15 − 20 μ m 15 - 20\,\mu\text{m} 15 − 20 μ m )

Nuclear-to-Cytoplasmic (N:C) Ratio Very high ( > 4 : 1 >4:1 > 4 : 1 ); scant cytoplasmic border High ( 3 : 1 to 4 : 1 3:1\text{ to }4:1 3 : 1 to 4 : 1 ); moderate cytoplasm

  • Chromatin Texture Homogeneous, dense, condensed, or finely stippled Delicate, fine, unaggregated, lacey
  • Nucleoli Inconspicuous, small, or absent (0 to 2) 2 to 5 prominent, distinct, pale nucleoli
  • Cytoplasm Scant, light blue; typically agranular Moderate, basophilic; may contain azurophilic granules
  • Auer Rods Strictly NEVER Present Present in 30–50% of cases (Pathognomonic)
  • 3. Lineage Immunophenotyping by Flow Cytometry

Definitive lineage assignment, developmental staging, and minimal residual disease (MRD) monitoring require multiparameter flow cytometric immunophenotyping: IMMUNOPHENOTYPIC SUBTYPES OF ALL

  • │
  • ┌──────────────────────────┴──────────────────────────┐
  • ▼ ▼
  • [ B-CELL PRECURSOR ALL ] [ T-CELL ALL ]
  • Pan-B: CD19, CD22, CD79a, Pax-5 • Lineage-Defining: cyCD3
  • Immature: CD34, TdT, CD10 (CALLA) • Pan-T: CD7 (earliest), CD2, CD5
  • Developmental Stages: • Cortical: CD1a
  • Pro-B: CD10- • Immature: CD4/CD8 double positive
  • Common B: CD10+ (CALLA+) or double negative, TdT+
  • Pre-B: Cytoplasmic mu+ (cmu+), sIg- • Mature: Surface CD3+
  • Mature B: Surface Ig+ (kappa/lambda restricted)
  • 1. B-Lymphoblastic Leukemia (B-ALL) Immunophenotypic Cascade

Pan-B Lineage Markers: CD19 , CD22 , CD79a , and the master B-cell transcription factor PAX-5 . CD20 expression is variable and acquires intensity during maturation.

Immature / Progenitor Antigens: CD34 , Terminal Deoxynucleotidyl Transferase (TdT) , and CD10 (CALLA - Common Acute Lymphoblastic Leukemia Antigen) .

Sequential Developmental Stages:

Pro-B ALL (Early Pre-B / FAB L1): CD19+, CD79a+, cyCD22+, TdT+, CD34+, CD10-negative . Highly correlated with KMT2A (11q23.3) translocations in infants.

Common B-ALL: CD19+, CD79a+, CD10-positive (CALLA+) , TdT+, CD34+. Represents the vast majority (~70%) of childhood B-ALL and carries the best general prognosis.

Pre-B ALL: CD19+, CD10+, cytoplasmic immunoglobulin μ \mu μ heavy chain positive ( c μ + c\mu^+ c μ + ) , surface immunoglobulin negative ( sIg − \text{sIg}^- sIg − ), TdT+.

Mature B-ALL (Burkitt-type Leukemia): Surface immunoglobulin positive ( sIg + \text{sIg}^+ sIg + ) with light chain restriction ( κ \kappa κ or λ \lambda λ ), CD19+, CD20+, CD10+, TdT negative or weak . Characterized by t ( 8 ; 14 ) ( q 24 ; q 32 ) t(8;14)(q24;q32) t ( 8 ; 14 ) ( q 24 ; q 32 ) MYC::IGH fusion.

2. T-Lymphoblastic Leukemia (T-ALL) Immunophenotypic Profile

Lineage-Defining Antigen: Cytoplasmic CD3 ( cyCD3 \text{cyCD3} cyCD3 ) is the essential, lineage-specific marker that definitively confirms T-cell commitment; surface CD3 (sCD3) appears later in thymic ontogeny.

Pan-T Antigens: CD7 (the earliest and most sensitive pan-T marker, present throughout all stages), CD2 , and CD5 .

Thymocyte Maturation Markers: CD1a (marker of cortical thymocytes), CD4 and CD8 double-positive ( C D 4 + C D 8 + CD4^+CD8^+ C D 4 + C D 8 + ) or double-negative ( C D 4 − C D 8 − CD4^-CD8^- C D 4 − C D 8 − ), and TdT positive .

Early T-cell Precursor (ETP-ALL): High-risk subtype defined by CD1a(-), CD8(-), CD5(weak < 75 % <75\% < 75% or absent), with co-expression of one or more myeloid/stem cell markers (CD34, CD117, HLA-DR, CD13, CD33).

4. Cytogenetic and Molecular Risk Stratification in ALL

Chromosomal and molecular abnormalities are the primary determinants of risk stratification and therapy intensity in ALL: CYTOGENETIC STRATIFICATION IN ALL

  • │
  • ┌──────────────────────────┴──────────────────────────┐
  • ▼ ▼
  • [ FAVORABLE PROGNOSIS ] [ UNFAVORABLE PROGNOSIS ]
  • Hyperdiploidy (>50 Chromosomes) • BCR::ABL1 [t(9;22) Minor Breakpoint p190]
  • ETV6::RUNX1 [t(12;21)] • KMT2A (MLL) Rearranged [t(4;11)]
  • Most common pediatric fusion (~25%) - Infant ALL (<1 yr), Pro-B (CD10-)
  • Excellent response to chemotherapy • Hypodiploidy (<44 Chromosomes)
  • Cure rate >90% • TCF3::HLF [t(17;19)]

Genetic Abnormality Chromosomal Translocation Prevalence Clinical Subtype Prognostic Impact

Hyperdiploidy > 50 >50 > 50 chromosomes (often 51–65; trisomies 4, 10, 17) 25 – 30% of pediatric B-ALL Common B-ALL (CD10+) Highly Favorable ; cure rate > 90 % >90\% > 90%

E T V 6 : : R U N X 1 ETV6::RUNX1 ET V 6 :: R U NX 1 (formerly TEL-AML1 ) t ( 12 ; 21 ) ( p 13.2 ; q 22.1 ) t(12;21)(p13.2;q22.1) t ( 12 ; 21 ) ( p 13.2 ; q 22.1 ) ~25% of pediatric B-ALL (most common) Common B-ALL (CD10+) Highly Favorable ; excellent chemotherapy response

B C R : : A B L 1 BCR::ABL1 BCR :: A B L 1 (Philadelphia Chromosome) t ( 9 ; 22 ) ( q 34.1 ; q 11.2 ) t(9;22)(q34.1;q11.2) t ( 9 ; 22 ) ( q 34.1 ; q 11.2 ) 25 – 30% of adult ALL; 3 – 5% of pediatric ALL Common or Pre-B ALL; high WBC count Historically Unfavorable / High Risk ; improved by TKIs (imatinib/dasatinib)

K M T 2 A KMT2A K MT 2 A ( M L L MLL M LL ) Rearranged t ( 4 ; 11 ) ( q 21 ; q 23.3 ) t(4;11)(q21;q23.3) t ( 4 ; 11 ) ( q 21 ; q 23.3 ) ~70–80% of infant ALL ( < 1 <1 < 1 year) Pro-B ALL (CD10-negative); high WBC, CNS disease Extremely Poor / Adverse

Hypodiploidy < 44 <44 < 44 chromosomes (near-haploid 24–31, low-hypodiploid 32–39) ~1 – 2% B-ALL Extremely Poor / High Risk

T C F 3 : : P B X 1 TCF3::PBX1 TCF 3 :: PBX 1 (formerly E2A-PBX1 ) t ( 1 ; 19 ) ( q 23 ; p 13.3 ) t(1;19)(q23;p13.3) t ( 1 ; 19 ) ( q 23 ; p 13.3 ) ~5% of pediatric ALL Pre-B ALL (cytoplasmic μ + \mu^+ μ + ) Intermediate risk (neutral with intensive therapy)

NOTCH1 / FBXW7 Mutations Activating gene mutations > 60 % >60\% > 60% of T-ALL cases T-ALL Favorable to neutral in T-ALL

Critical Board Contrast — Philadelphia Chromosome Breakpoints: In Chronic Myeloid Leukemia (CML), the translocation breakpoint occurs in the major breakpoint cluster region (M-bcr) , producing a 210-kDa oncoprotein (p210) . In contrast, in Philadelphia-positive ALL (Ph+ ALL) , the breakpoint occurs in the minor breakpoint cluster region (m-bcr) , producing a 190-kDa oncoprotein (p190) in > 70 % >70\% > 70% of cases.

5. Cytochemical Profile of ALL

While flow cytometry has superseded cytochemistry for detailed subtyping, specific cytochemical reactions remain high-yield on certification exams: ALL CYTOCHEMICAL PROFILE

  • ┌─────────────────────────────────────────────────────────────┐
  • │ 1. Terminal Deoxynucleotidyl Transferase (TdT): │
  • │ • Nuclear enzyme; POSITIVE in >95% of B-ALL and T-ALL │
  • │ • Strictly negative in mature B-cells and AML │
  • │ 2. Periodic Acid-Schiff (PAS): │
  • │ • "CHUNKY BLOCK" cytoplasmic positivity against clear │
  • │ background in 50–70% of lymphoblasts (glycogen) │
  • │ 3. Myeloperoxidase (MPO) & Sudan Black B (SBB): │
  • │ • STRICTLY NEGATIVE (excludes myeloid lineage) │
  • │ 4. Acid Phosphatase (AP): │
  • │ • T-ALL: FOCAL POLAR (PARANUCLEAR / GOLGI) DOT POSITIVE │
  • │ • B-ALL: Negative or weak diffuse │
  • └─────────────────────────────────────────────────────────────┘

Terminal Deoxynucleotidyl Transferase (TdT): A template-independent DNA polymerase that adds non-templated N-nucleotides to V-D-J gene segments during TCR and immunoglobulin heavy chain gene rearrangement. Demonstrates strong nuclear positivity in > 95 % >95\% > 95% of precursor B-ALL and T-ALL lymphoblasts, but is negative in mature B-cell malignancies (Burkitt leukemia), AML, and non-hematopoietic tumors.

Periodic Acid-Schiff (PAS): Stains intracellular glycogen and carbohydrate macromolecules. Approximately 50–70% of ALL cases display classic coarse "chunky block" or granular cytoplasmic positivity against a completely clear background, contrasting with the diffuse pink blush seen in maturing granulocytes.

Myeloperoxidase (MPO) and Sudan Black B (SBB): Strictly negative in ALL, providing unequivocal distinction from AML.

Acid Phosphatase (AP): In T-ALL, the lysosomal enzyme acid phosphatase is localized to the Golgi apparatus, producing a diagnostic focal, polar, paranuclear dot-like precipitate , whereas B-ALL is negative or weakly diffuse.

Loading diagram... Immunophenotypic and Cytogenetic Decision Matrix for Precursor Lymphoid Neoplasms (ALL)